141 related articles for article (PubMed ID: 38063874)
1. Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study.
Bilgic A; Kodjikian L; de Ribot FM; Spitzer MS; Vasavada V; Gonzalez-Cortes JH; Sudhalkar A; Chakraborty S; Mathis T
Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1161-1167. PubMed ID: 38063874
[TBL] [Abstract][Full Text] [Related]
2. Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study.
Bilgic A; Kodjikian L; March de Ribot F; Vasavada V; Gonzalez-Cortes JH; Abukashabah A; Sudhalkar A; Mathis T
J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34201729
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
[TBL] [Abstract][Full Text] [Related]
4. Brolucizumab for Wet Age-Related Macular Degeneration: One-Year Real-World Experience from a Tertiary Center.
Scupola A; Carlà MM; Boselli F; Giannuzzi F; De Filippis A; Fossataro C; Minnella AM; D'Amico G; Coppola G; Savastano MC; Sammarco MG; Rizzo S
Ophthalmologica; 2023; 246(1):58-67. PubMed ID: 36843038
[TBL] [Abstract][Full Text] [Related]
5. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
[TBL] [Abstract][Full Text] [Related]
6. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
7. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.
Bulirsch LM; Saßmannshausen M; Nadal J; Liegl R; Thiele S; Holz FG
Br J Ophthalmol; 2022 Sep; 106(9):1288-1294. PubMed ID: 33846161
[TBL] [Abstract][Full Text] [Related]
8. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
[TBL] [Abstract][Full Text] [Related]
9. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
[TBL] [Abstract][Full Text] [Related]
10. Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.
Chronopoulos A; Huynh E; Ashurov A; Schutz JS; Jonas JB; Hattenbach LO
Eur J Ophthalmol; 2024 Mar; 34(2):487-496. PubMed ID: 37461836
[TBL] [Abstract][Full Text] [Related]
11. Brolucizumab in recalcitrant neovascular age-related macular degeneration-real-world data in Chinese population.
Weng CC; Chi SC; Lin TC; Huang YM; Chou YB; Hwang DK; Chen SJ
PLoS One; 2024; 19(4):e0301096. PubMed ID: 38564612
[TBL] [Abstract][Full Text] [Related]
12. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
13. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
14. HAWK Extension Study: Safety and Efficacy of Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration.
Brown DM; Nowik M; Bouillaud E; Dugel APU;
Curr Eye Res; 2023 Jan; 48(1):44-50. PubMed ID: 36398628
[No Abstract] [Full Text] [Related]
15. Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients.
Gesualdo C; Rossi S; Iodice CM; Guarino F; Petrella M; D'Agostino FA; Perrotta R; Simonelli F
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374314
[No Abstract] [Full Text] [Related]
16. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
[TBL] [Abstract][Full Text] [Related]
17. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
[TBL] [Abstract][Full Text] [Related]
18. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
[TBL] [Abstract][Full Text] [Related]
19. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry.
MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA
Ophthalmology; 2023 Sep; 130(9):937-946. PubMed ID: 37086857
[TBL] [Abstract][Full Text] [Related]
20. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
